Moreover, comparing the last two groups in Fig. 4 (groups 5 and 6), PLGA-ICG-R837-based PTT plus anti-CTLA4 induced the highest percentage of CD8+ CTLs (also the CD8+ CTL/Treg ratio), which are primarily responsible for cell immunity in cancer immunotherapy. Here, CTLA4 is linked to cancer.